Financial Results for Quarter Ended June 30, 2026.

CIN No. L24232PB1983PLC005426 GST No. 03AAACK6458M1ZB Phone : 91-8558820862 (Accounts) : 91-8558820863 (Admin.) CD ® D.L. No. 1800-0SP, 1804-B I.E. Code No. 1293001210 : 91-9915743720 (Exports) KWALITY PHARMACEUTICALS LIMITED M.D. Mobile: 91-9814071215, 9814052314 E-mail : export@kwalitypharma.com Regd. Office: Village Nag KaIan, Majitha Road, Amritsar - 143 601 (INDIA) ramesh@kwalitypharma.com Website : www.kwalitypharma.com Date: August 10, 2026 The Department of Corporate Services, BSE Limited Phiroze Jeejeebhoy Towers Dalai Street, Mumbai - 400001 Subject: Submission of standalone and consolidated unaudited financial results for the quarter ended on 30.06.2026 under Regulation 33 of the SEBI (LODR) Regulations, 2015 Ref: Scrip Code: 539997 With respect to captioned subject, we wish to inform you that the Board of Directors in its Meeting held today has inter-alia, considered and approved the standalone and consolidated Unaudited Financial Results for the quarter ended June 30, 2026. We are submitting herewith the standalone and consolidated unaudited financial results under Regulation 33 of the Securities and Exchange board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the quarter ended as on 30.06.2026 along with the Auditors limited review reports thereon. The Board Meeting of the Company commenced at 10:30 a.m. and concluded at 11:55 a.m. Kindly take the above on your record. Yours Faithfully, For KWALITY PHAR ., .- RAMESH KUMAR Managing Director DIN: 00462656 CIN No. L24232PB1983PLC005426 GST No. 03AAACK6458M1ZB Phone : 91-8558820862 (Accounts) : 91-8558820863 (Admin.) 0 ® D.L. No. 1800-0SP, 1804-B I.E. Code No. 1293001210 : 91-9915743720 (Exports) KWALITY PHARMACEUTICALS LIMITED M.D. Mobile: 91-9814071215, 9814052314 E-mail : export@kwalitypharma.com Regd. Office: Village Nag KaIan, Majitha Road, Amritsar - 143 601 (INDIA) ramesh@kwalitypharma.com Website : www.kwalitypharma.com Management Discussion and Analysis — Q1 FY27 Kwality Pharmaceuticals Ltd. ("KPL") delivered a strong start to FY27, extending its track record of disciplined execution, expanding regulatory footprint, and growing presence in complex, high-barrier product segments. In Q1FY27, consolidated revenue grew 46% year-on-year to t162 crore from t112 crore in Q1FY26, and rose 3% QoQ from 157 crore in Q4FY26. EBITDA increased to t 41 crore from 37 crore in Q1FY26, an increase of 13% YoY, with margins expanding from 21.9% to 25.3% (up from 24.8% in Q4FY26), reflecting continued operating leverage and a stronger product mix. PAT surged 119% YoY to 26 crore from t12 crore, with margins improving sharply from 11% to 16%; on a QoQ basis, PAT grew 3% with margins holding steady at 16%. Building on this momentum and a strong FY26 base, management has raised FY27 guidance across all key metrics: revenue to 700+ crore (+39%+ YoY), EBITDA to t189-196+ crore (27-28%+ margin), and PAT to 109+ crore (-15.5%+ margin). During the quarter, KPL advanced its R&D and clinical programme, completing 13 Bioequivalence (BE) studies — 7 from the General unit, 2 from Beta Lactam, and 4 from Oncology as part of its 40 molecule BE programme (including 3 injectables and 37 OSDs). Filings for completed BE studies have already been made in 15+ countries, with further filings underway, reinforcing KPL's push into regulated markets. The company also secured 15+ new key product registrations during the quarter across Malaysia, Algeria, Peru and Mexico. On the biologics front, KPL received approval to initiate pre-clinical batches for Pembrolizumab, adding a second biologics candidate alongside Erythropoietin, which has now progressed to the clinical trial stage. Construction of the Hormone manufacturing facility remains on schedule, with completion anticipated by November 2026. The company operates five state-of-the-art manufacturing facilities, accredited by premier global regulators such as PIC/S (including ANVISA and SFDA), INVIMA, DIGEMID, and EU-GMP. This robust regulatory foundation establishes KPL as a research-driven front runner in complex and niche injectables, with a presence in over 70+ co VIJAY MEHRA & CO. CHARTERED ACCOUNTANTS INDIA Head Office: D-351, Ranjit Avenue, Amritsar. CA Amit Handa CA Ashish Raja CA Radhika Goel F.C.A DISA (ICAI), LL.B, LL.M F.C.A. Dip. IFRS B.Com F.C.A , B.com (Hons.) (Partner) (Partner) (Partner) 9878887600 9899032170 9915460831 Ref: Date: I el qj INDEPENDENT AUDITOR'S REVIEW REPORT ON QUARTERLY UNAUDITED STAND .ALONE FINANCIAL RESULTS OF THE COMPANY FOR QUARTER ENDED 30' JUNE , 2026 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS,2015 (AS AMENDED) The Board of Directors of Kwality Pharmaceuticals Limited. I. We have re k ie‘Ned the accompanying- statement of standalone unaudited financial results of tiwality Pharmaceuticals Limited ("the company) for the quarter ended on 30th June , 2026. being submitted b) the Company pursuant to the requirement of Regulation 33 of the SF.131 (Listing Obligations and Disclosure Requirements) Regulations. 2015 (as amended). 2. This Statement. which is the responsibility of the Company's Management and approved b) the Compan)'s Board of Directors. has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting- (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance ‘N. ith Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations. 2015. Our responsibility is to issue a report on the Statement based on our review. 3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity-, issued b) the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an auch e not BRANCH OFFICES: * C-2, UGF, FRONT SIDE, RAJAPURI ROAD, NEAR SHANTI NURSING HOME, UTTAM NAGAR, NEW -110059 10-E, MALVIYA COMPLEX, LANE NEXT TO NO EXIT, MOHAN MALVIYA ROAD, AMRITSAR - 143001 Email : vijaymehraca@gmailcom, caamithanda@gmail.com, caashishra/a09@gmail.com, caradhikagoel@gmail.com VIJAY MEHRA & CO. CHARTERED ACCOUNTANTS INDIA Head Office: D-351, Ranjit Avenue, Amritsar. CA Amit Handa CA Ashish Raja 111 CA Radhika Goel F.C.A DISA LL.B, LL.M F.C.A. Dip. IFRS B.Com F.C.A, B.com (Hons.) (Partner) (Partner) (Partner) 9878887600 9899032170 9915460831 Ref Date: performed an audit and accordingly. we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with applicable Indian Accounting Standards (" Ind AS-) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement. For VIJAY MEHRA & CO. Chartered Accountants CA \ l' HANDA Place: Amritsar Partner Date: 10-08-2026 M. No: 502400 ERN: 001051N UDIN:-26502400AYBZEH2450 BRANCH OFFICES: C-2, UGF, FRONT SIDE, RAJAPURI ROAD, NEAR SHANTI NURSING HOME, UTTAM NAGAR, NEW DELHI - 110059 10-E, MALVIYA COMPLEX, LANE NEXT TO NO EXIT, MOHAN MALVIYA ROAD, AMRITSAR -143001 Email : vijaymehraca@gmail.com, caamithanda@gmail.com, caashishraja09@gmail.com, caradhikagoel@gma [Showing first 8,000 characters — download PDF for full document]